Redcare Pharmacy (DE:RDC)
XETRA:RDC
Want to see DE:RDC full AI Analyst Report?
Top Page
Redcare Pharmacy
(XETRA:RDC)
Select Model
Select Model
Rating:44Neutral
Price Target:
€48.00
▼(-4.95% Downside)
Action:Reiterated
Date:05/09/26
The score is primarily held back by weak financial quality—persistent net losses and deeply negative TTM free cash flow—despite strong revenue growth and improving EBITDA. Technically, the stock remains in a broader downtrend (well below 100DMA/200DMA) with only mixed momentum signals. Valuation is also constrained by negative earnings (negative P/E) and no dividend support.
Positive Factors
Strong revenue growth
Sustained ~21.6% revenue growth signals expanding market share and customer adoption across its online pharmacy platforms. Over 2-6 months this revenue momentum underpins scale benefits, supports supplier leverage and marketing efficiency, and provides a base to improve unit economics.
Negative Factors
Persistent net losses
Ongoing negative net income erodes retained earnings and constrains the company’s ability to self-fund growth. Even with improving EBITDA, failure to convert to net profits means continued dependence on external capital and sustained pressure on equity compounding over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
Sustained ~21.6% revenue growth signals expanding market share and customer adoption across its online pharmacy platforms. Over 2-6 months this revenue momentum underpins scale benefits, supports supplier leverage and marketing efficiency, and provides a base to improve unit economics.
Read all positive factors
Redcare Pharmacy (RDC) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€1.01B
Dividend YieldN/A
Average Volume (3M)132.76K
Price to Earnings (P/E)―
Beta (1Y)1.55
Revenue Growth21.58%
EPS Growth22.79%
CountryDE
Employees1,827
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-1.86
Shares Outstanding20,578,390
10 Day Avg. Volume128,637
30 Day Avg. Volume132,758
Financial Highlights & Ratios
PEG Ratio1.97
Price to Book (P/B)2.85
Price to Sales (P/S)0.45
P/FCF Ratio-23.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€74.21Price Target Upside46.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.74
Revenue Forecast (FY)€3.35B
Redcare Pharmacy Business Overview & Revenue Model
Company Description
Redcare Pharmacy N.V. manages and runs a network of digital pharmacies across Germany, Austria, Switzerland, France, Belgium, Italy, and the Netherlands. The company offers a comprehensive selection of healthcare products, including prescription m...
How the Company Makes Money
Redcare Pharmacy primarily makes money by selling pharmacy and health-related products online. Its core revenue stream is product sales to end customers (B2C), which generally includes (1) prescription medications (where permitted and depending on...
Redcare Pharmacy Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
56
Neutral
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.07B | 2.94B | 2.37B | 1.80B | 1.20B | 1.06B |
| Gross Profit | 632.18M | 593.70M | 545.78M | 440.38M | 331.79M | 266.53M |
| EBITDA | 69.72M | 45.60M | 28.03M | 50.94M | -30.64M | -37.41M |
| Net Income | -37.38M | -37.70M | -45.46M | -12.04M | -77.65M | -74.19M |
Balance Sheet | ||||||
| Total Assets | 1.18B | 1.25B | 1.00B | 1.02B | 729.47M | 783.08M |
| Cash, Cash Equivalents and Short-Term Investments | 135.00M | 203.50M | 177.56M | 204.16M | 184.00M | 283.46M |
| Total Debt | 354.80M | 415.60M | 247.38M | 244.84M | 255.19M | 236.43M |
| Total Liabilities | 710.10M | 767.30M | 493.31M | 469.56M | 374.84M | 367.66M |
| Stockholders Equity | 450.20M | 459.20M | 483.98M | 522.19M | 354.63M | 415.41M |
Cash Flow | ||||||
| Free Cash Flow | -89.74M | -56.30M | 13.38M | 23.23M | -82.64M | -31.52M |
| Operating Cash Flow | 10.85M | 23.00M | 22.13M | 61.46M | -29.11M | 11.63M |
| Investing Cash Flow | -80.41M | -151.40M | 8.38M | -59.96M | -138.01M | -84.30M |
| Financing Cash Flow | 58.38M | 124.10M | -17.94M | 15.05M | -13.52M | 229.59M |
Redcare Pharmacy Technical Analysis
Positive
50.50
Price Trends
44.87
Positive
50.17
Negative
60.99
Negative
Market Momentum
0.72
Negative
57.17
Neutral
63.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:RDC, the sentiment is Positive. The current price of 50.5 is above the 20-day moving average (MA) of 46.43, above the 50-day MA of 44.87, and below the 200-day MA of 60.99, indicating a neutral trend. The MACD of 0.72 indicates Negative momentum. The RSI at 57.17 is Neutral, neither overbought nor oversold. The STOCH value of 63.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:RDC.
Redcare Pharmacy Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | €1.43B | 43.42 | 4.19% | 0.20% | 1.16% | -43.53% | |
60 Neutral | €14.76M | 16.29 | 3.75% | 3.46% | -23.48% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
44 Neutral | €1.01B | -26.36 | -7.79% | ― | 21.58% | 22.79% | |
43 Neutral | €121.17M | -3.03 | -5460.56% | ― | -53.03% | -94.45% |
* General Sector Average
DE:RDC
Redcare Pharmacy
49.00
-50.05
-50.53%
DE:B8FK
Biofrontera
2.57
0.07
2.80%
DE:COP
CompuGroup Medical
27.10
5.46
25.20%
DE:GME
Geratherm Medical
2.71
-0.42
-13.50%
DE:HPHA
Heidelberg Pharma AG
2.59
-1.96
-43.08%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.